Thursday, 15 October 2026European Markets
Via News Knowledge File

NASDAQ

organization100% conf.·synced Oct 15, 2026

Stock exchange where Jayud is listed

14
sourced metrics
1661
relationships
5
stated objectives
8
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Recovery Time From Prior Peak
15years
Stock Price
91.14USD
Index Level
23548.88points
Weekly Return
6percent
Listed Companies
3500companies
Index Change
-1percent
Minimum Bid Price
1.00USD
Market Return
185percent
Apr 4, 2026source
Percent Change
-2.4percent
Mar 27, 2026source
Daily Return
-0.59percent
Mar 25, 2026source
Daily Change
1percent
Feb 25, 2026source
Return
20percent
Dec 26, 2025source
Market Cap Multiple
5times_dotcom_peak
Jan 1, 2025source
Stock Index Decline
80percent
Oct 1, 2002source

Stated objectives

Start tokenization operations

source
by 2026-01-01 00:00:00stated

Obtain approval for 23-hour weekday trading

source
target: 23 hours per weekday stated

Allow stocks to be tokenized and traded on regulated venues

source
stated

Nasdaq expanding into tokenized securities following SEC approval, aiming to bring traditional securities onto the blockchain

source
stated

Nasdaq taking steps toward listing tokenized stocks where on-chain tokens represent real-world equities

source
stated

Relationship graph · 1661 connections

listed on
1082
located in
366
regulates
60
trades on
24
headquartered in
19
Owns
14
Covered by
11
Supplies to
10

Via News coverage

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com